Fabio Calabrò

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 716 citations · Full text

Factorial Design, Urology, × 2 +9

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

Cora N. Sternberg, Daniel P. Petrylak, Oliver Sartor et al. · Journal of Clinical Oncology · 2009 · 339 citations · Full text

Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

Evan Y. Yu, George Wilding, Edwin M. Posadas et al. · Clinical Cancer Research · 2009 · 218 citations · Full text

Can patient selection for bladder preservation be based on response to chemotherapy?

Cora N. Sternberg, Vito Pansadoro, Fabio Calabrò et al. · Cancer · 2003 · 159 citations

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

Cora N. Sternberg, Herlinde Dumez, Hendrik Van Poppel et al. · Annals of Oncology · 2009 · 123 citations

Urology, Oblimersen Sodium, Genitourinary Cancer +9